p53 dependent and independent sensitivity to oxaliplatin of colon cancer cells

Biochemical Pharmacology

Volumn 74, Issue 3, 2007, Pages 392-406

  Toscano, Florent ^a,b,c   Parmentier, Béatrice ^a,b,c   Fajoui, Zineb El ^a,b,c   Estornes, Yann ^a,b,c   Chayvialle, Jean Alain ^a,b,c   Saurin, Jean Christophe ^a,b,c   Abello, Jacques ^a,b,c  

^a INSERM   (France)

^b IFR Laënnec 62   (France)

^c UNIVERSITÉ LYON 1   (France)

Author keywords

Apoptosis; Cell cycle; Chemosensitivity; Colorectal cancer; Oxaliplatin; p53

Indexed keywords

CASPASE 3; CISPLATIN; DNA; MUTANT PROTEIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; OXALIPLATIN; PROTEIN P21; PROTEIN P51; PROTEIN P53; SMALL INTERFERING RNA; TRANSPLATIN;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL STRAIN HCT116; CLINICAL ARTICLE; COLORECTAL CANCER; CONTROLLED STUDY; DNA CLEAVAGE; DRUG EXPOSURE; DRUG RESISTANCE; DRUG SENSITIVITY; ENZYME ACTIVATION; ENZYME ACTIVITY; HUMAN; HUMAN CELL; IC 50; MUTATION; PRIORITY JOURNAL; WILD TYPE;

EID: 34250723431     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2007.05.001     Document Type: Article

References (39)

1. Giacchetti S., Perpoint B., Zidani R., Le Bail N., Faggiuolo R., Focan C., et al. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 18 (2000) 136-147
2. Rixe O., Ortuzar W., Alvarez M., Parker R., Reed E., Paull K., et al. Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's Anticancer Drug Screen panel. Biochem Pharmacol 52 (1996) 1855-1865
3. Kweekel D.M., Gelderblom H., and Guchelaar H.J. Pharmacology of oxaliplatin and the use of pharmacogenomics to individualize therapy. Cancer Treat Rev 31 (2005) 90-105
4. Gourdier I., Del Rio M., Crabbe L., Candeil L., Copois V., Ychou M., et al. Drug specific resistance to oxaliplatin is associated with apoptosis defect in a cellular model of colon carcinoma. FEBS Lett 529 (2002) 232-236
5. Bunz F., Hwang P.M., Torrance C., Waldman T., Zhang Y., Dillehay L., et al. Disruption of p53 in human cancer cells alters the responses to therapeutic agents. J Clin Invest 104 (1999) 263-269
6. Arango D., Corner G.A., Wadler S., and Catalano P.J. Augenlicht LH. c-myc/p53 interaction determines sensitivity of human colon carcinoma cells to 5-fluorouracil in vitro and in vivo. Cancer Res 61 (2001) 4910-4915
7. Bhonde M.R., Hanski M.L., Budczies J., Cao M., Gillissen B., Moorthy D., et al. DNA damage-induced expression of p53 suppresses mitotic checkpoint kinase hMps1: the lack of this suppression in p53MUT cells contributes to apoptosis. J Biol Chem 281 (2006) 8675-8685
8. Magrini R., Bhonde M.R., Hanski M.L., Notter M., Scherubl H., Boland C.R., et al. Cellular effects of CPT-11 on colon carcinoma cells: dependence on p53 and hMLH1 status. Int J Cancer 101 (2002) 23-31
9. Vousden K.H., and Lu X. Live or let die: the cell's response to p53. Nat Rev Cancer 2 (2002) 594-604
10. Vogelstein B., Lane D., and Levine A.J. Surfing the p53 network. Nature 408 (2000) 307-310
11. Yu J., and Zhang L. The transcriptional targets of p53 in apoptosis control. Biochem Biophys Res Commun 331 (2005) 851-858
12. Blandino G., Levine A.J., and Oren M. Mutant p53 gain of function: differential effects of different p53 mutants on resistance of cultured cells to chemotherapy. Oncogene 18 (1999) 477-485
13. Arango D., Wilson A.J., Shi Q., Corner G.A., Aranes M.J., Nicholas C., et al. Molecular mechanisms of action and prediction of response to oxaliplatin in colorectal cancer cells. Br J Cancer 91 (2004) 1931-1946
14. Boyer J., McLean E.G., Aroori S., Wilson P., McCulla A., Carey P.D., et al. Characterization of p53 wild-type and null isogenic colorectal cancer cell lines resistant to 5-fluorouracil, oxaliplatin, and irinotecan. Clin Cancer Res 10 (2004) 2158-2167
15. Gourdier I., Crabbe L., Andreau K., Pau B., and Kroemer G. Oxaliplatin-induced mitochondrial apoptotic response of colon carcinoma cells does not require nuclear DNA. Oncogene 23 (2004) 7449-7457
16. Arnould S., Hennebelle I., Canal P., Bugat R., and Guichard S. Cellular determinants of oxaliplatin sensitivity in colon cancer cell lines. Eur J Cancer 39 (2003) 112-119
17. Andre T., Boni C., Mounedji-Boudiaf L., Navarro M., Tabernero J., Hickish T., et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 350 (2004) 2343-2351
18. Maurici D., Monti P., Campomenosi P., North S., Frebourg T., Fronza G., et al. Amifostine (WR2721) restores transcriptional activity of specific p53 mutant proteins in a yeast functional assay. Oncogene 20 (2001) 3533-3540
19. Gayet J., Zhou X.P., Duval A., Rolland S., Hoang J.M., Cottu P., et al. Extensive characterization of genetic alterations in a series of human colorectal cancer cell lines. Oncogene 20 (2001) 5025-5032
20. Schwartz GK. Development of cell cycle active drugs for the treatment of gastrointestinal cancers: a new approach to cancer therapy. J Clin Oncol 23 (2005) 4499-4508
21. Wang D., and Lippard S.J. Cellular processing of platinum anticancer drugs. Nat Rev Drug Discov 4 (2005) 307-320
22. Irwin M.S., Kondo K., Marin M.C., Cheng L.S., Hahn W.C., and Kaelin Jr. W.G. Chemosensitivity linked to p73 function. Cancer Cell 3 (2003) 403-410
23. Melino G., De Laurenzi V., and Vousden KH. p73: friend or foe in tumorigenesis. Nat Rev Cancer 2 (2002) 605-615
24. Ehrsson H., Wallin I., and Yachnin J. Pharmacokinetics of oxaliplatin in humans. Med Oncol 19 (2002) 261-265
25. Abraham M.C., and Shaham S. Death without caspases, caspases without death. Trends Cell Biol 14 (2004) 184-193
26. Basu A., and Haldar S. The relationship between BcI2, Bax and p53: consequences for cell cycle progression and cell death. Mol Hum Reprod 4 (1998) 1099-1109
27. Waldman T., Lengauer C., Kinzler K.W., and Vogelstein B. Uncoupling of S phase and mitosis induced by anticancer agents in cells lacking p21. Nature 381 (1996) 713-716
28. Johnstone R.W., Ruefli A.A., and Lowe S.W. Apoptosis: a link between cancer genetics and chemotherapy. Cell 108 (2002) 153-164
29. de Vries A., Flores E.R., Miranda B., Hsieh H.M., van Oostrom C.T., Sage J., et al. Targeted point mutations of p53 lead to dominant-negative inhibition of wild-type p53 function. Proc Natl Acad Sci USA 99 (2002) 2948-2953
30. Chipuk J.E., and Green D.R. p53's believe it or not: lessons on transcription-independent death. J Clin Immunol 23 (2003) 355-361
31. Erster S., Mihara M., Kim R.H., Petrenko O., and Moll U.M. In vivo mitochondrial p53 translocation triggers a rapid first wave of cell death in response to DNA damage that can precede p53 target gene activation. Mol Cell Biol 24 (2004) 6728-6741
32. Gasco M., and Crook T. p53 family members and chemoresistance in cancer: what we know and what we need to know. Drug Resist Updat 6 (2003) 323-328
33. Zaika A.I., Slade N., Erster S.H., Sansome C., Joseph T.W., Pearl M., et al. DeltaNp73, a dominant-negative inhibitor of wild-type p53 and TAp73, is up-regulated in human tumors. J Exp Med 196 (2002) 765-780
34. Chen X., Zheng Y., Zhu J., Jiang J., and Wang J. p73 is transcriptionally regulated by DNA damage, p53, and p73. Oncogene 20 (2001) 769-774
35. Zhu J., Jiang J., Zhou W., and Chen X. The potential tumor suppressor p73 differentially regulates cellular p53 target genes. Cancer Res 58 (1998) 5061-5065
36. Ishida S., Yamashita T., Nakaya U., and Tokino T. Adenovirus-mediated transfer of p53-related genes induces apoptosis of human cancer cells. Jpn J Cancer Res 91 (2000) 174-180
37. Flores E.R., Tsai K.Y., Crowley D., Sengupta S., Yang A., McKeon F., et al. p63 and p73 are required for p53-dependent apoptosis in response to DNA damage. Nature 416 (2002) 560-564
38. Gaiddon C., Lokshin M., Ahn J., Zhang T., and Prives C. A subset of tumor-derived mutant forms of p53 down-regulate p63 and p73 through a direct interaction with the p53 core domain. Mol Cell Biol 21 (2001) 1874-1887
39. Bergamaschi D., Gasco M., Hiller L., Sullivan A., Syed N., Trigiante G., et al. p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis. Cancer Cell 3 (2003) 387-402